Search results for "Platelet Aggregation"

showing 10 items of 155 documents

A Polyunsaturated Fatty Acid Diet Lowers Blood Pressure and Improves Antioxidant Status in Spontaneously Hypertensive Rats

2001

gamma-Linolenic acid [GLA, 18:3(n-6)], eicosapentaenoic acid [EPA, 20:5(n-3)] and docosahexaenoic acid [DHA, 22:6(n-3)] have been reported to prevent cardiovascular diseases. However, they are highly unsaturated and therefore more sensitive to oxidation damage. We investigated the effects of a diet rich in these polyunsaturated fatty acids (PUFA) on blood pressure, plasma and lipoprotein lipid concentrations, total antioxidant status, lipid peroxidation and platelet function in spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto rats (WKY). Five-week-old SHR and WKY rats were fed for 10 wk either a diet containing Isio 4 oil or a diet rich in GLA, EPA and DHA (5.65, 6.39 and…

Lipid Peroxidesmedicine.medical_specialtyTime FactorsAntioxidantDocosahexaenoic AcidsPlatelet AggregationThiobarbituric acidmedicine.medical_treatmentMedicine (miscellaneous)Blood PressureBiologyRats Inbred WKYAntioxidantsLipid peroxidationchemistry.chemical_compoundRats Inbred SHRInternal medicinemedicineAnimalsgamma-Linolenic Acidgamma-Linolenic acidchemistry.chemical_classificationNutrition and DieteticsDietary FatsLipidsEicosapentaenoic acidRatsEndocrinologyEicosapentaenoic AcidchemistryDocosahexaenoic acidHypertensionFatty Acids Unsaturatedlipids (amino acids peptides and proteins)LipoproteinPolyunsaturated fatty acidThe Journal of Nutrition
researchProduct

Resveratrol: preventing properties against vascular alterations and ageing.

2005

International audience; Cardiovascular diseases are the leading cause of death in developed countries where the common pathological substrate underlying this process is atherosclerosis. Several new concepts have emerged in relation to mechanisms that contribute to the regulation of the vascular diseases and associated inflammatory effects. Recently, potential antioxidants (vitamin E, polyphenols) have received much attention as potential anti-atherosclerotic agents. Among the polyphenols with health benefic properties, resveratrol, a phytoalexin of grape, seem to be a good candidate protecting the vascular walls from oxidation, inflammation, platelet aggregation, and thrombus formation. In …

MESH : Oxidative StressAgingAntioxidantPlatelet AggregationArteriosclerosismedicine.medical_treatmentResveratrolPharmacologymedicine.disease_causeMuscle Smooth Vascularchemistry.chemical_compoundMESH : VasodilationMESH : Foam CellsMESH : Platelet AggregationStilbenesMESH : Cardiovascular DiseasesMESH : Macrophageschemistry.chemical_classificationNeovascularization PathologicPhytoalexinfood and beveragesVasodilationBiochemistryCardiovascular Diseasesmedicine.symptomBiotechnologyLipoproteinsInflammationHealth PromotionMESH : LipoproteinsBiologyMESH : StilbenesMESH : ArteriosclerosismedicineHumans[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyReactive oxygen speciesMechanism (biology)MacrophagesMESH : HumansMESH : Neovascularization PathologicMESH : Muscle Smooth VascularMESH : AgingOxidative StresschemistryAgeingResveratrolMESH : Health PromotionOxidative stressFood ScienceFoam Cells
researchProduct

Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism - results from clinical observa…

2020

Background: The pathogenesis of arterial and venous thrombosis is in large part interlaced. How much platelet phenotype relates to acute venous thromboembolism (VTE) independent of the underlying cardiovascular profile is presently poorly investigated.Methods: Platelet count and mean platelet volume (MPV), platelet aggregation in whole blood and platelet rich plasma (PRP), platelet-dependent thrombin generation (TG) and platelet surface activation markers were measured under standardized conditions. Machine learning was applied to identify the most relevant characteristics associated with VTE from a large array (N = 58) of clinical and plateletrelated variables.Findings: VTE cases (N = 159)…

Male0301 basic medicinePlatelet Aggregationlcsh:MedicineDETERMINANTSGastroenterologyMachine LearningPathogenesisACTIVATION0302 clinical medicineRisk FactorsPlateletWhole bloodlcsh:R5-920AspirinOUTCOMESThrombinVenous ThromboembolismGeneral MedicineMiddle AgedThrombosisVenous thrombosis030220 oncology & carcinogenesisAcute DiseaseFemaleDisease Susceptibilitylcsh:Medicine (General)Research Papermedicine.drugBlood Plateletsmedicine.medical_specialtyPlatelet Function TestsGeneral Biochemistry Genetics and Molecular BiologyImmunophenotyping03 medical and health sciencesACUTE PULMONARY-EMBOLISMRISK-FACTORInternal medicinemedicineHumansMean platelet volumeMETAANALYSISAgedPlatelet Countbusiness.industrylcsh:RPlatelet Activationmedicine.diseasePREVENTIONASPIRINTHROMBOSIS030104 developmental biologyPlatelet-rich plasmaVOLUMEbusinessBiomarkersEBioMedicine
researchProduct

Mediterranean Diet Decreases the Initiation of Use of Vitamin K Epoxide Reductase Inhibitors and Their Associated Cardiovascular Risk: A Randomized C…

2020

Our aim is to assess whether following a Mediterranean Diet (MedDiet) decreases the risk of initiating antithrombotic therapies and the cardiovascular risk associated with its use in older individuals at high cardiovascular risk. We evaluate whether participants of the PREvenci&oacute

Male0301 basic medicineVitamin KTime FactorsMediterranean diet030204 cardiovascular system & hematologyPharmacology4-HydroxycoumarinsDiet Mediterraneanchemistry.chemical_compound0302 clinical medicinepreventionAntithromboticNutsEnzyme InhibitorsDiet Fat-RestrictedUncategorizedNutrition and DieteticsMiddle AgedClopidogrelVitamines KCardiovascular Diseasesrandomized controlled trialsRandomized controlled trialsPlatelet aggregation inhibitorDietaFemaleVitamin K epoxide reductaselcsh:Nutrition. Foods and food supplymedicine.druglcsh:TX341-641Article03 medical and health sciencesMediterranean cookingFibrinolytic AgentsMediterranean dietVitamin K Epoxide ReductasesPlatelet aggregation inhibitorsCuina mediterràniamedicineHumansTiclopidineplatelet aggregation inhibitorsOlive OilAgedMediterranean DietMalalties cardiovascularsbusiness.industryPreventionWarfarinDiet4-hydroxycoumarins030104 developmental biologychemistryHeart Disease Risk FactorsbusinessFood Science
researchProduct

The prescription of direct oral anticoagulants in the elderly: An observational study of 19 798 Ambulatory subjects.

2020

International audience; Objective Direct oral anticoagulants (DOACs) are increasingly prescribed to elderly people, but the epidemiologic data for this population remains scarce. We compared the elderly population taking DOACs and those not taking DOACs (noDOAC). Method We included individuals over 75 years old, affiliated to Mutualite Sociale Agricole of Burgundy (a French regional health insurance agency), who had been refunded for a prescribed DOAC between 1st and 30th September 2017. The DAOC group (DAOCG) and noDOAC group (noDOACG) were compared in terms of demographic conditions, registered chronic diseases (RCD), and number and types of prescribed drugs. In the DOACG, we compared the…

MaleAdministration Oral030204 cardiovascular system & hematologyKidney Function Tests0302 clinical medicineRivaroxabanMedicineDisease030212 general & internal medicineProspective StudiesPractice Patterns Physicians'Aged 80 and overeducation.field_of_studyFrailtyVenous ThromboembolismGeneral MedicineMetaanalysisManagement3. Good healthDabigatranHealthCreatinineAmbulatoryPlatelet aggregation inhibitorApixabanFemaleBlood Coagulation TestsFranceSafetymedicine.drugmedicine.medical_specialtyPyridonesPopulationDrug PrescriptionsDabigatran03 medical and health sciencesInternal medicineHumansMedical prescriptioneducationAntihypertensive AgentsAgedRivaroxabanbusiness.industryWarfarinAnticoagulantsBlood Cell CountAtrial-FibrillationChronic DiseasePyrazolesWarfarinbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyPlatelet Aggregation InhibitorsInternational journal of clinical practiceREFERENCES
researchProduct

''Assessment of the use of hypolipidemic agents (HAs), mainly statins, in elderly subjects aged 80 years and more in Burgundy: Analysis of 13,211 pat…

2012

Manckoundia, Patrick | Lorenzini, Mathieu | Disson-Dautriche, Anne | Petit, Jean-Michel | Lorcerie, Bernard | Debost, Emmanuel | Menu, Didier | Pfitzenmeyer, Pierre; International audience; ''Only few studies have investigated the use of HA in elderly subjects and there are no data in very elderly subjects. We assessed the prescription of HA and analyzed the relationship between such prescriptions and frailty markers among persons aged 80 and more in an observational study. We recorded the prescriptions for 13,211 patients aged 80-109 years and affiliated to the "Mutualite-Sociale-Agricole (MSA)'' of Burgundy over a 1-month period. The prescription of a HA among all included patients, and t…

MaleAgingHealth (social science)DiseaseCoronary Artery Disease030204 cardiovascular system & hematologylaw.invention0302 clinical medicineRandomized controlled triallawAVERAGE CHOLESTEROL LEVELS030212 general & internal medicineStrokeHypolipidemic AgentsAged 80 and overFibric AcidsOPEN-LABEL3. Good healthCONTROLLED TRIALHypertensionFemaleFranceSTROKEmedicine.drugmedicine.medical_specialtyAdrenergic beta-AntagonistsDrug Prescriptions03 medical and health sciencesPeripheral Arterial DiseaseDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansCORONARY-HEART-DISEASEMedical prescriptionCARDIOVASCULAR EVENTSMORTALITY''Polypharmacybusiness.industryMORTALITY[SCCO.NEUR]Cognitive science/NeuroscienceCardiovascular Agentsmedicine.disease''CORONARY-HEART-DISEASEPRAVASTATINPhysical therapyPolypharmacyRISK-FACTORSObservational studyGeriatrics and GerontologyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPRIMARY PREVENTIONGerontologyPravastatinPlatelet Aggregation Inhibitors
researchProduct

Prescription of Antithrombotic Therapy in Older Patients Hospitalized for Transient Ischemic Attack and Ischemic Stroke: The GIFA Study

2004

Background and Purpose— Antithrombotic therapy has been demonstrated as an effective tool for secondary ischemic stroke prevention. Nevertheless, scant data are available on actual prescription of this therapy in clinical practice. Methods— A total of 17 337 patients admitted to geriatric and internal medicine wards participating in the study in the 1993 to 1998 survey period were analyzed. Patients with coded diagnoses of ischemic stroke and transient ischemic attack (TIA) were selected. Data recorded included demographic and clinical characteristics and medication prescription during hospital stay and at discharge. Logistic regression analyses were used to identify conditions associated …

MaleAgingmedicine.medical_specialtypharmacoepidemiologyEpidemiologymedicine.drug_classIschemiaMedication prescriptionNOBrain Ischemiastroke; prevention; aging; antithrombotic therapy; pharmacoepidemiologypreventionFibrinolytic AgentsEpidemiologyAntithromboticmedicineHumansMedical prescriptionStrokeAgedDemographyAntithrombotic therapyAdvanced and Specialized Nursingbusiness.industryAnticoagulantAnticoagulantsOdds ratiomedicine.diseaseHospitalizationStrokeIschemic Attack TransientAcute DiseaseEmergency medicinePhysical therapyFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsStroke
researchProduct

Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A…

2016

Summary Objective In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction. In this retrospective analysis, we evaluated drug efficacy in subgroups of patients, according to a history of diabetes mellitus. Methods The primary study endpoint was 1-year combined occurrence of death or hospitalization for cardiovascular causes. Diabetes was defined according to medical history (previous known diagnosis). Results A total of 562 of 693 (81.0%) patients were classified as nondiabetics and 131 (18.9%) as dia…

MaleCaptoprilDiabetic CardiomyopathiesMyocardial InfarctionInfarctionAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologychemistry.chemical_compoundVentricular Dysfunction Left0302 clinical medicineDiabetes mellitusRamiprilRetrospective StudieCardiovascular DiseaseMedicinePharmacology (medical)030212 general & internal medicineMyocardial infarctionDiabetic CardiomyopathieRandomized Controlled Trials as TopicAspirinLeft ventricular dysfunctionGeneral MedicineAcetyl salicylic acid; Acute myocardial infarction; Angiotensin-converting enzyme inhibitors; Diabetes mellitus; Left ventricular dysfunction; Ramipril; Zofenopril; Cardiology and Cardiovascular Medicine; Pharmacology (medical); PharmacologyMiddle AgedZofenoprilAcetyl salicylic acidCardiovascular DiseasesCardiologyPlatelet aggregation inhibitorDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugHumanRamiprilmedicine.medical_specialtyDiabetes mellituSystoleAcute myocardial infarctionZofenopril03 medical and health sciencesDiabetes mellitusInternal medicineHumansAgedRetrospective StudiesPharmacologyAspirinbusiness.industryPlatelet Aggregation InhibitorAngiotensin-Converting Enzyme Inhibitormedicine.diseasechemistryAngiotensin-converting enzyme inhibitorbusinessMacePlatelet Aggregation Inhibitors
researchProduct

Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acut…

2012

Background: Angiotensin-converting enzyme inhibitors (ACEIs) are largely employed for treating patients with left ventricular dysfunction (LVD), but their efficacy may be negatively affected by concomitant administration of acetylsalicylic acid (ASA), with some difference among the different compounds. Hypothesis: The interaction between ASA and the two ACEIs zofenopril and ramipril may result in a different impact on survival of cardiac patients, due to differences in the pharmacological properties of the two ACEIs. Methods: This phase IIIb, randomized, double-blind, parallel-group, multicenter, European study compared the safety and efficacy of zofenopril (60 mg/day) and ramipril (10 mg/d…

MaleCaptoprilTime FactorsMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateVentricular Function Leftlaw.inventionchemistry.chemical_compoundVentricular Dysfunction LeftRandomized controlled trialRamiprillawRisk FactorsOdds RatioMyocardial infarctionProspective Studieseducation.field_of_studyEjection fractionGeneral MedicineMiddle AgedZofenoprilEuropeHospitalizationTreatment OutcomeCardiologyDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugRamiprilmedicine.medical_specialtySystolePopulationClinical InvestigationsRisk AssessmentDouble-Blind MethodInternal medicinemedicineHumanseducationAgedHeart FailureChi-Square DistributionAspirinbusiness.industryStroke Volumeacetylsalicylic acidmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareSurgeryLogistic ModelschemistryAngiotensin-converting enzyme inhibitorHeart failureMyocardial infarction complicationsZofenopril ramipril myocardial infarctionbusinessPlatelet Aggregation Inhibitors
researchProduct

Patients with coronary artery disease and diabetes need improved management : a report from the EUROASPIRE IV survey: a registry from the EuroObserva…

2015

Background: In order to influence every day clinical practice professional organisations issue management guidelines. Cross-sectional surveys are used to evaluate the implementation of such guidelines. The present survey investigated screening for glucose perturbations in people with coronary artery disease and compared patients with known and newly detected type 2 diabetes with those without diabetes in terms of their life-style and pharmacological risk factor management in relation to contemporary European guidelines. Methods: A total of 6187 patients (18-80 years) with coronary artery disease and known glycaemic status based on a self reported history of diabetes (previously known diabet…

MaleEUROASPIRE InvestigatorsCardiac & Cardiovascular SystemsCross-sectional studyEndocrinology Diabetes and MetabolismAngiotensin-Converting Enzyme InhibitorsBlood PressureCoronary Artery DiseaseType 2 diabetesGUIDELINESCoronary artery diseaseMELLITUSRisk FactorsGlycaemic controlMedicine and Health SciencesSecondary PreventionCoronary artery disease ; Type 2 diabetes ; Secondary prevention ; Management ; Guideline adherence ; Blood lipids ; Blood pressure ; Glycaemic controlCardiac and Cardiovascular SystemsRegistriesMyocardial infarctionGLUCOSE CONTROLOriginal InvestigationBLOOD-GLUCOSEType 2 diabetesMiddle AgedManagementEuropeglycaemic controlHypertensionPractice Guidelines as TopicHEARTPlatelet aggregation inhibitorFemaletype 2 diabetesGuideline AdherenceCardiology and Cardiovascular MedicineLife Sciences & Biomedicinemanagementmedicine.medical_specialtyCardiotonic AgentsAdrenergic beta-Antagonists/Endocrinology and Diabetes1102 Cardiovascular Medicine And HaematologyEndocrinology & MetabolismAngiotensin Receptor AntagonistsSDG 3 - Good Health and Well-beingInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentsddc:610Risk factorAntihypertensive AgentsAgedDyslipidemiasScience & Technologyblood lipidsbusiness.industryMORTALITYCholesterol LDLmedicine.diseaseCross-Sectional StudiesBlood pressureCardiovascular System & HematologyMYOCARDIAL-INFARCTIONDiabetes Mellitus Type 2Cardiovascular System & CardiologyBlood lipidsCARDIOVASCULAR-DISEASESRISK-FACTORSHydroxymethylglutaryl-CoA Reductase InhibitorsFOLLOW-UPbusinessPlatelet Aggregation Inhibitors
researchProduct